AstraZeneca PLC
AZN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $54,073,000 | $45,811,000 | $44,351,000 | $37,417,000 |
| % Growth | 18% | 3.3% | 18.5% | – |
| Cost of Goods Sold | $10,207,000 | $8,268,000 | $12,391,000 | $12,437,000 |
| Gross Profit | $43,866,000 | $37,543,000 | $31,960,000 | $24,980,000 |
| % Margin | 81.1% | 82% | 72.1% | 66.8% |
| R&D Expenses | $13,583,000 | $10,935,000 | $9,762,000 | $9,736,000 |
| G&A Expenses | $19,669,000 | $17,683,000 | $17,448,000 | $15,144,000 |
| SG&A Expenses | $20,224,000 | $18,222,000 | $17,984,000 | $15,590,000 |
| Sales & Mktg Exp. | $555,000 | $539,000 | $536,000 | $446,000 |
| Other Operating Expenses | $56,000 | $193,000 | $457,000 | -$1,402,000 |
| Operating Expenses | $33,863,000 | $29,350,000 | $28,203,000 | $23,924,000 |
| Operating Income | $10,003,000 | $8,193,000 | $3,757,000 | $1,056,000 |
| % Margin | 18.5% | 17.9% | 8.5% | 2.8% |
| Other Income/Exp. Net | -$1,312,000 | -$1,294,000 | -$1,256,000 | -$1,321,000 |
| Pre-Tax Income | $8,691,000 | $6,899,000 | $2,501,000 | -$265,000 |
| Tax Expense | $1,650,000 | $938,000 | -$792,000 | -$380,000 |
| Net Income | $7,035,000 | $5,955,000 | $3,288,000 | $112,000 |
| % Margin | 13% | 13% | 7.4% | 0.3% |
| EPS | 1.14 | 1.91 | 1.06 | 0.04 |
| % Growth | -40.3% | 80.2% | 2,550% | – |
| EPS Diluted | 1.13 | 1.91 | 1.06 | 0.04 |
| Weighted Avg Shares Out | 3,100,000 | 3,124,000 | 3,096,000 | 2,836,000 |
| Weighted Avg Shares Out Dil | 3,126,000 | 3,124,000 | 3,120,000 | 2,854,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $345,000 | $301,000 | $81,000 | $43,000 |
| Interest Expense | $1,682,000 | $1,589,000 | $1,330,000 | $1,276,000 |
| Depreciation & Amortization | $5,065,000 | $4,934,000 | $5,254,000 | $4,102,000 |
| EBITDA | $15,438,000 | $13,422,000 | $9,085,000 | $5,113,000 |
| % Margin | 28.6% | 29.3% | 20.5% | 13.7% |